Lyell Immunopharma更新Lyl273在复发或难治性转移性结直肠癌中的安全性数据，并将一期试验扩展为一/二期

美股速递06-08 18:02

Lyell Immunopharma公司宣布，已就其候选药物Lyl273在治疗复发或难治性转移性结直肠癌患者中的安全性概况提供了最新信息。同时，公司决定将原计划的一期临床试验方案修订并扩展为一/二期试验。此举旨在进一步评估该疗法的安全性与初步疗效，为后续的临床开发路径收集更全面的数据。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1135624151?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-08 18:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135624151","market":"us","top_or_hot":-1,"title":"Lyell Immunopharma更新Lyl273在复发或难治性转移性结直肠癌中的安全性数据，并将一期试验扩展为一/二期","media":"美股速递","content":"<p>Lyell Immunopharma公司宣布，已就其候选药物Lyl273在治疗复发或难治性转移性结直肠癌患者中的安全性概况提供了最新信息。同时，公司决定将原计划的一期临床试验方案修订并扩展为一/二期试验。此举旨在进一步评估该疗法的安全性与初步疗效，为后续的临床开发路径收集更全面的数据。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lyell Immunopharma更新Lyl273在复发或难治性转移性结直肠癌中的安全性数据，并将一期试验扩展为一/二期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLyell Immunopharma更新Lyl273在复发或难治性转移性结直肠癌中的安全性数据，并将一期试验扩展为一/二期\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-08 18:02 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lyell Immunopharma公司宣布，已就其候选药物Lyl273在治疗复发或难治性转移性结直肠癌患者中的安全性概况提供了最新信息。同时，公司决定将原计划的一期临床试验方案修订并扩展为一/二期试验。此举旨在进一步评估该疗法的安全性与初步疗效，为后续的临床开发路径收集更全面的数据。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LYEL","symbol_name":"Lyell Immunopharma, Inc.","start_time":0,"source_url":"","article_id":"1135624151","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135624151","pubTimestamp":1780912947,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Lyell Immunopharma公司宣布，已就其候选药物Lyl273在治疗复发或难治性转移性结直肠癌患者中的安全性概况提供了最新信息。同时，公司决定将原计划的一期临床试验方案修订并扩展为一/二期试验。此举旨在进一步评估该疗法的安全性与初步疗效，为后续的临床开发路径收集更全面的数据。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LYEL":"Lyell Immunopharma, Inc.","BK4139":"生物科技","BK4539":"次新股","BK4505":"高瓴资本持仓"},"translate_title":"Lyell Immunopharma updates safety data for Lyl273 in relapsed or refractory metastatic colorectal cancer and expands phase I trial to phase I/II","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LYEL":1},"content_text":"Lyell Immunopharma公司宣布，已就其候选药物Lyl273在治疗复发或难治性转移性结直肠癌患者中的安全性概况提供了最新信息。同时，公司决定将原计划的一期临床试验方案修订并扩展为一/二期试验。此举旨在进一步评估该疗法的安全性与初步疗效，为后续的临床开发路径收集更全面的数据。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135624151","isCrawlerRequest":true}